Loading...
Harmony Biosciences Q1 2025 Earnings Report
Harmony Biosciences reported strong Q1 2025 financial results, highlighting advancement of its pipeline and upcoming catalysts, and reaffirmed 2025 revenue guidance.
Key Takeaways
Harmony Biosciences reported strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, building on four consecutive years of profitability, and increased cash and investments to over $600 million on the balance sheet.
WAKIX® net revenue was $184.7 million for Q1 2025, representing 20% growth year-over-year.
Net income grew 19% year-over-year, continuing a trend of four consecutive years of profitability.
Completed recruitment of the Phase 3 registrational trial of ZYN002 in Fragile X Syndrome, with topline data expected in Q3.
On track to initiate Phase 3 registrational trials for next-generation Pitolisant-HD in narcolepsy and IH in Q4 2025.
Revenue by Segment
Forward Guidance
Harmony Biosciences expects full year 2025 net product revenue to be between $820 million and $860 million, driven by continued commercial success and upcoming pipeline catalysts.
Positive Outlook
- Reiterated 2025 net revenue guidance of $820-$860 million.
- Topline data for ZYN002 in Fragile X Syndrome expected in Q3 2025, potentially leading to the first approved treatment for this patient community.
- BP1.15205, a potential best-in-class orexin, will have data presented at SLEEP 2025 in June.
- Initiation of next-generation Pitolisant-HD Phase 3 registrational trials in narcolepsy and IH on track for Q4 2025.
- Utility patents for Pitolisant HD filed out to 2044 for narcolepsy and IH.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- Potential delays in clinical trials or regulatory approvals could impact future timelines.
- Market acceptance and clinical utility of new indications or product candidates are not guaranteed.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...